Importance of Real-World Data in Supporting Treatment Options

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

EP: 5.EMERALD-1 Study Results

EP: 6.Discussion and Summary

EP: 7.LEAP-012 Study Results

EP: 8.Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP: 9.ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP: 10.Choosing Second-Line Therapies: Considering First Line Therapy Received

EP: 11.Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP: 12.CELESTIAL Sub-Group Discussion

EP: 13.Discussion of RESORCE Trial

EP: 14.Real-World Treatment Data from the Phase 4 STELLAR Trial

Now Viewing

EP: 15.Importance of Real-World Data in Supporting Treatment Options

EP: 16.CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

EP: 17.Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

Video content above is prompted by the following:

Dr. El- Khoueiry: Real-world data gives a different perspective on approved treatments,: essentially, how the therapy performs off -trial. Please discuss the findings from the real-world study focusing on real-world eligibility for cabozantinib, regorafenib, and ramucirumab in second-line treatment.
• Discuss the difference in strict eligibility criteria (SEC) compared towith liberal modified eligibility criteria [MEC, including ECOG score of 2, and Child-Pugh- score of B7] (Fung AS, et al. Cancer Med. 2020).